Merck CEO on Keytruda Injection Approval and Vaccine Landscape

Keytruda Injection Approval

• 💉 Keytruda injection is an advancement for cancer patients, reducing infusion time from 30 minutes to approximately one minute.
• 🏥 This new formulation offers patients greater choice in where they receive treatment, moving beyond hospitals and infusion centers to doctor's offices and community health centers.
• ⏱️ The reduced treatment time and increased accessibility aim to help patients manage cancer more like a chronic disease rather than a life sentence.
• ⚠️ The approval does not extend the patent for the IV form of Keytruda, and biosimilar competition is still expected for the original formulation.

Pricing and Future Strategy

• 💰 Merck plans to price the injectable version at parity with the IV infusion to encourage adoption, not as a price-hiking strategy.
• 📈 The company anticipates 30-40% of patients may switch to the new injectable form.
• 🚀 Merck is focused on growth through over 20 new asset launches in the next five years, with significant revenue potential beyond Keytruda.
• 🌟 While no single drug is expected to replicate Keytruda's massive success, Merck aims for blockbuster potential across multiple new oncology assets and leadership in other therapeutic areas.

Navigating the Vaccine Landscape

• 🛡️ Vaccines are highlighted as critical public health tools that prevent devastating diseases like polio and measles.
• 📉 Merck expresses concern over recent CDC vaccine advisory committee recommendations, noting a lack of new science supporting changes to the established schedule.
• ⚠️ There is a worry that vaccine hesitancy, fueled by misinformation, could lead to a resurgence of preventable diseases.
• ✅ Merck stands firmly behind the safety and effectiveness of its vaccines, emphasizing the robust, peer-reviewed clinical studies conducted.